上海医药(601607.SH)：醋酸艾司利卡西平片获得美国FDA批准文号

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for Eslicarbazepine Acetate Tablets has been approved for marketing [1] Group 1 - The approved drug, Eslicarbazepine Acetate Tablets, is indicated for the treatment of partial-onset seizures in patients aged 4 years and older [1]